サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584135

神経内分泌腫瘍治療市場：治療タイプ別、薬剤クラス別、腫瘍タイプ別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測

Neuroendocrine Tumor Treatment Market, By Therapy Type, By Drug Class, By Tumor Type, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 316 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
神経内分泌腫瘍治療市場：治療タイプ別、薬剤クラス別、腫瘍タイプ別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 316 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

神経内分泌腫瘍（NET）治療市場規模は2023年に25億1,021万米ドルとなり、2024年から2032年にかけてCAGR 9.10%で拡大

神経内分泌腫瘍治療市場-市場力学

臨床試験数の増加が神経内分泌腫瘍治療市場のイノベーションを加速

臨床試験件数の増加が神経内分泌腫瘍治療市場のイノベーションを大幅に加速しており、標的治療法の開発にますます焦点が当てられていることを反映しています。例えば、2021年、米国国立衛生研究所（NIH）は、NETに特化した350以上の活発な臨床試験を報告し、新たな治療の道を探る緊急性を強調しています。ノバルティスやイプセンなどの製薬会社は、ソマトスタチン類似体やペプチド受容体放射性核種療法（PRRT）などの新規薬剤を評価する臨床研究に多額の投資を行っています。さらに、欧州神経内分泌腫瘍学会（European Neuroendocrine Tumor Society：ENETS）のようなイニシアチブは、共同研究の推進に役立っており、治療プロトコルの迅速な進歩を可能にしています。その結果、神経内分泌腫瘍と診断された患者の転帰と生活の質を向上させる有望な新しい治療法が生まれることが期待されています。

神経内分泌腫瘍治療市場-主要洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約9.10%のCAGRで毎年成長すると予測されています。

治療タイプ別では、ソマトスタチン類似体療法が2023年に最大の市場シェアを示すと予測されます。

薬剤クラス別では、2023年にソマトスタチン類似体が主要タイプに

腫瘍タイプ別では、消化管膵神経内分泌腫瘍（GEP-NET）が2023年に主要タイプになります。

地域別では、北米が2023年の主要収益源であった

神経内分泌腫瘍治療市場-セグメンテーション分析：

世界の神経内分泌腫瘍治療市場は、治療タイプ、薬剤クラス別、腫瘍タイプ、エンドユーザー別、地域別に区分されます。

市場は治療タイプに基づいて4つのカテゴリーに分けられる：すなわち、ソマトスタチン類似体療法、ペプチド受容体放射性核種療法（PRRT）、標的療法、化学療法です。ソマトスタチン類似体療法は、症状管理における有効性が確立されているため、トップです。これに僅差で続くのがペプチド受容体放射性核種治療（PRRT）で、標的治療の牽引役となっています。標的療法と化学療法も、優先順位は低いが重要です。

市場は薬剤クラス別に4つに分類される：ソマトスタチン類似体、チロシンキナーゼ阻害剤、mTOR阻害剤、アルキル化剤です。ソマトスタチン類似体は、症状や腫瘍増殖の管理に有効であるため、最も優先順位が高いです。mTOR阻害剤とアルキル化剤も重要であるが、優先順位は低いです。

神経内分泌腫瘍治療市場-地理的洞察

神経内分泌腫瘍（NET）治療市場は、有病率、治療オプション、調査活動において大きな地域差を示します。北米は、先進的なヘルスケアインフラと腫瘍学研究への多額の投資により、主要地域として際立っており、米国がん協会によると、米国では毎年約12,000人の新規NET症例が報告されています。欧州も重要な役割を果たしており、特にドイツや英国では、欧州神経内分泌腫瘍学会（ENETS）のようなイニシアチブが研究者や臨床医の連携を促進し、治療プロトコルと治療へのアクセスを強化しています。アジア太平洋では、中国やインドなどの新興市場が神経内分泌腫瘍の認知度と診断率の上昇を目の当たりにしており、医療提供者に治療選択肢の拡大を促しています。さらに、日本神経内分泌腫瘍学会のようなイニシアチブは、神経内分泌腫瘍の理解と管理の改善に取り組んでおり、市場の存在感を高める一因となっています。その結果、これらの地域情勢別洞察は、治療の進歩や調査の重点度が異なるダイナミックな状況を示しています。

神経内分泌腫瘍治療市場-競合情勢：

神経内分泌腫瘍（NET）治療市場の競合情勢は、製薬大手や専門バイオテクノロジー企業など、多様なプレーヤーによって特徴付けられます。Novartis社やIpsen社などの大手企業が最前線にあり、SandostatinやSomatulineなどの治療薬が対症療法と腫瘍制御の市場を独占しています。2023年、ノバルティスはサンドスタチンの売上高を20億米ドル超と報告し、その市場シェアの大きさを強調しています。Advanced Accelerator Applications（ノバルティスの子会社）やClovis Oncologyのような新興プレーヤーは、放射性リガンド治療や標的治療などの革新的な治療で躍進しており、臨床現場で人気を集めています。バイエルやファイザーのような企業が買収や合併を通じて製品ポートフォリオを強化しようとする中、共同研究や戦略的提携も盛んで、特にバイエルは標的放射性核種治療用のルテチウムLu177の権利を取得しています。さらに、研究開発への注力は依然として高く、新規治療法を模索する数多くの臨床試験が実施されており、NET治療における患者の転帰の改善を目指した活気に満ちた競合環境を反映しています。

目次

第1章 神経内分泌腫瘍治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 神経内分泌腫瘍治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 神経内分泌腫瘍治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 神経内分泌腫瘍治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 神経内分泌腫瘍治療市場情勢

  • 神経内分泌腫瘍治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 神経内分泌腫瘍治療市場- 治療タイプ別

  • 概要
    • 治療タイプ別セグメントシェア分析
    • ソマトスタチン類似体療法
    • ペプチド受容体放射性核種療法（PRRT）
    • 標的療法
    • 化学療法

第8章 神経内分泌腫瘍治療市場-薬剤クラス別

  • 概要
    • 薬剤クラス別セグメントシェア分析
    • ソマトスタチン類似体
    • チロシンキナーゼ阻害剤
    • mTOR阻害剤
    • アルキル化剤

第9章 神経内分泌腫瘍治療市場- 腫瘍タイプ別

  • 概要
    • 腫瘍タイプ別セグメントシェア分析
    • 消化管膵神経内分泌腫瘍（GEP-NET）
    • 肺神経内分泌腫瘍
    • その他

第10章 神経内分泌腫瘍治療市場- エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院
    • がん専門クリニック
    • 調査機関

第11章 神経内分泌腫瘍治療市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- 神経内分泌腫瘍治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Novartis AG
    • Pfizer Inc.
    • Ipsen SA
    • Advanced Accelerator Applications SA
    • Merck &Co., Inc.
    • AstraZeneca PLC
    • Roche Holding AG
    • Bristol-Myers Squibb Company
    • Bayer AG
    • GlaxoSmithKline plc
    • Eli Lilly and Company
    • Sanofi SA
    • Boehringer Ingelheim GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Hutchison China MediTech Limited（Hutchmed）
    • Lexicon Pharmaceuticals, Inc.
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV4115

REPORT HIGHLIGHT

Neuroendocrine Tumor Treatment Market size was valued at USD 2,510.21 Million in 2023, expanding at a CAGR of 9.10% from 2024 to 2032.

The Neuroendocrine Tumor Treatment Market focuses on therapies designed to manage neuroendocrine tumors (NETs), which originate from neuroendocrine cells and can occur in various organs. With an increasing global incidence of NETs-affecting approximately 6.98 cases per 100,000 people-the demand for effective treatment options is on the rise. Rising awareness about NETs, advancements in targeted therapies, and the growing number of clinical trials contribute significantly to market growth. However, high treatment costs and a lack of knowledge among healthcare professionals can hinder market expansion. Opportunities lie in the development of novel therapeutics and combination therapies, along with the potential for personalized medicine, which could enhance treatment efficacy. As healthcare systems evolve, the integration of advanced diagnostic techniques, such as PET scans and molecular imaging, is anticipated to improve patient outcomes and drive further growth in the market.

Neuroendocrine Tumor Treatment Market- Market Dynamics

Growing Number of Clinical Trials Accelerates Innovation in the Neuroendocrine Tumor Treatment Market

The growing number of clinical trials is significantly accelerating innovation in the neuroendocrine tumor (NET) treatment market, reflecting an increasing focus on developing targeted therapies. For instance, in 2021, the National Institutes of Health (NIH) reported over 350 active clinical trials specifically for NETs, highlighting the urgency to explore new treatment avenues. Pharmaceutical companies such as Novartis and Ipsen have invested heavily in clinical research to evaluate novel agents, including somatostatin analogs and peptide receptor radionuclide therapy (PRRT). Furthermore, initiatives like the European Neuroendocrine Tumor Society (ENETS) have been instrumental in promoting collaborative research efforts, enabling faster advancements in treatment protocols. As a result, these efforts are anticipated to yield promising new therapies that enhance patient outcomes and quality of life for those diagnosed with neuroendocrine tumors.

Neuroendocrine Tumor Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 9.10% over the forecast period (2024-2032)

Based on Therapy Type segmentation, Somatostatin Analog Therapy was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Somatostatin Analogs was the leading type in 2023

Based on Tumor Type segmentation, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) were the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Neuroendocrine Tumor Treatment Market- Segmentation Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Therapy Type, Drug Class, Tumor Type, End-User, and Region.

The market is divided into four categories based on Therapy Type: Somatostatin Analog Therapy, Peptide Receptor Radionuclide Therapy (PRRT), Targeted Therapy, and Chemotherapy. Somatostatin Analog Therapy leads due to its established efficacy in symptom management. Following closely is Peptide Receptor Radionuclide Therapy (PRRT), gaining traction for targeted treatment. Targeted Therapy and Chemotherapy are also important, albeit with lower priority.

The market is divided into four categories based on Drug Class: Somatostatin Analogs, Tyrosine Kinase Inhibitors, mTOR Inhibitors, and Alkylating Agents. Somatostatin Analogs hold the highest priority due to their effectiveness in managing symptoms and tumor growth. Tyrosine Kinase Inhibitors follow, offering targeted action. mTOR Inhibitors and Alkylating Agents are also significant but with lower priority.

Neuroendocrine Tumor Treatment Market- Geographical Insights

The neuroendocrine tumor (NET) treatment market exhibits significant geographical variations in prevalence, treatment options, and research activities. North America stands out as the leading region, driven by advanced healthcare infrastructure and substantial investment in oncology research, with the U.S. reporting approximately 12,000 new NET cases annually according to the American Cancer Society. Europe also plays a crucial role, particularly in countries like Germany and the UK, where initiatives like the European Neuroendocrine Tumor Society (ENETS) foster collaboration among researchers and clinicians to enhance treatment protocols and access to therapies. In Asia-Pacific, emerging markets such as China and India are witnessing increasing awareness and diagnosis rates of neuroendocrine tumors, prompting healthcare providers to expand treatment options. Additionally, initiatives like the Japanese Society of Neuroendocrine Tumors are working to improve the understanding and management of NETs, thereby contributing to a growing market presence. As a result, these geographical insights indicate a dynamic landscape with varying levels of treatment advancements and research emphasis.

Neuroendocrine Tumor Treatment Market- Competitive Landscape:

The competitive landscape of the neuroendocrine tumor (NET) treatment market is characterized by a diverse array of players, including pharmaceutical giants and specialized biotech companies. Leading organizations such as Novartis and Ipsen are at the forefront, with their drugs, including Sandostatin and Somatuline, dominating the market for symptomatic treatment and tumor control. In 2023, Novartis reported over $2 billion in sales for Sandostatin, underscoring its significant market share. Emerging players like Advanced Accelerator Applications (a Novartis subsidiary) and Clovis Oncology are making strides with innovative therapies, including radioligand treatments and targeted therapies, which are gaining traction in clinical settings. Collaborations and strategic partnerships are also prevalent, as companies like Bayer and Pfizer seek to enhance their product portfolios through acquisitions and mergers, notably Bayer's acquisition of the rights to Lutetium Lu 177 for targeted radionuclide therapy. Furthermore, the focus on research and development remains high, with numerous clinical trials exploring novel treatment modalities, reflecting a vibrant and competitive environment aimed at improving patient outcomes in NET treatment.

Recent Developments:

In January 2024, the FDA's approval of Lu 177-dotatate (Lutathera) as an initial treatment for advanced neuroendocrine tumors, showed significant improvements in progression-free survival and tumor shrinkage when combined with octreotide, enhancing therapeutic options for patients.

In March 2024, the FDA granted breakthrough therapy designation to AlphaMedix (212Pb-DOTAMTATE) for treating advanced gastroenteropancreatic neuroendocrine tumors. This marks a significant advancement as it is the first targeted alpha therapy to receive this status, expediting its development.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Pfizer Inc.
  • Ipsen S.A.
  • Advanced Accelerator Applications S.A.
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Bayer AG
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Sanofi S.A.
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Hutchison China MediTech Limited (Hutchmed)
  • Lexicon Pharmaceuticals, Inc.
  • Others

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Somatostatin Analog Therapy
  • Peptide Receptor Radionuclide Therapy (PRRT)
  • Targeted Therapy
  • Chemotherapy

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Somatostatin Analogs
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • Alkylating Agents

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY TUMOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
  • Lung Neuroendocrine Tumors
  • Others

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Specialty Clinics
  • Research Institutes

GLOBAL NEUROENDOCRINE TUMOR TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroendocrine Tumor Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroendocrine Tumor Treatment Market Snippet by Therapy Type
    • 2.1.2. Neuroendocrine Tumor Treatment Market Snippet by Drug Class
    • 2.1.3. Neuroendocrine Tumor Treatment Market Snippet by Tumor Type
    • 2.1.4. Neuroendocrine Tumor Treatment Market Snippet by End-User
    • 2.1.5. Neuroendocrine Tumor Treatment Market Snippet by Country
    • 2.1.6. Neuroendocrine Tumor Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroendocrine Tumor Treatment Key Market Trends

  • 3.1. Neuroendocrine Tumor Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroendocrine Tumor Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroendocrine Tumor Treatment Market Opportunities
  • 3.4. Neuroendocrine Tumor Treatment Market Future Trends

4. Neuroendocrine Tumor Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroendocrine Tumor Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Neuroendocrine Tumor Treatment Market Landscape

  • 6.1. Neuroendocrine Tumor Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroendocrine Tumor Treatment Market - By Therapy Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy Type, 2023 & 2032 (%)
    • 7.1.2. Somatostatin Analog Therapy
    • 7.1.3. Peptide Receptor Radionuclide Therapy (PRRT)
    • 7.1.4. Targeted Therapy
    • 7.1.5. Chemotherapy

8. Neuroendocrine Tumor Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 8.1.2. Somatostatin Analogs
    • 8.1.3. Tyrosine Kinase Inhibitors
    • 8.1.4. mTOR Inhibitors
    • 8.1.5. Alkylating Agents

9. Neuroendocrine Tumor Treatment Market - By Tumor Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Tumor Type, 2023 & 2032 (%)
    • 9.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    • 9.1.3. Lung Neuroendocrine Tumors
    • 9.1.4. Others

10. Neuroendocrine Tumor Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Cancer Specialty Clinics
    • 10.1.4. Research Institutes

11. Neuroendocrine Tumor Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Neuroendocrine Tumor Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Neuroendocrine Tumor Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Neuroendocrine Tumor Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Neuroendocrine Tumor Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Neuroendocrine Tumor Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Tumor Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroendocrine Tumor Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Novartis AG
    • 12.2.2. Pfizer Inc.
    • 12.2.3. Ipsen S.A.
    • 12.2.4. Advanced Accelerator Applications S.A.
    • 12.2.5. Merck & Co., Inc.
    • 12.2.6. AstraZeneca PLC
    • 12.2.7. Roche Holding AG
    • 12.2.8. Bristol-Myers Squibb Company
    • 12.2.9. Bayer AG
    • 12.2.10. GlaxoSmithKline plc
    • 12.2.11. Eli Lilly and Company
    • 12.2.12. Sanofi S.A.
    • 12.2.13. Boehringer Ingelheim GmbH
    • 12.2.14. Teva Pharmaceutical Industries Ltd.
    • 12.2.15. Hutchison China MediTech Limited (Hutchmed)
    • 12.2.16. Lexicon Pharmaceuticals, Inc.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us